Literature DB >> 31349904

PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer.

Holly Fowle1, Ziran Zhao1, Xavier Graña2.   

Abstract

PP2A is a highly conserved eukaryotic serine/threonine protein phosphatase of the PPP family of phosphatases with fundamental cellular functions. In cells, PP2A targets specific subcellular locations and substrates by forming heterotrimeric holoenzymes, where a core dimer consisting of scaffold (A) and catalytic (C) subunits complexes with one of many B regulatory subunits. PP2A plays a key role in positively and negatively regulating a myriad of cellular processes, as it targets a very sizable fraction of the cellular substrates phosphorylated on Ser/Thr residues. This review focuses on insights made toward the understanding on how the subunit composition and structure of PP2A holoenzymes mediates substrate specificity, the role of substrate modulation in the signaling of cellular division, growth, and differentiation, and its deregulation in cancer.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B55α; Cancer; Cell cycle; PP2A holoenzyme; PPP2R2A; Phosphorylation; Retinoblastoma protein (pRB); Serine/threonine protein phosphatases; Substrate specificity; p107

Mesh:

Substances:

Year:  2019        PMID: 31349904     DOI: 10.1016/bs.acr.2019.03.009

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  12 in total

Review 1.  Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 2.  Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.

Authors:  Jie Pan; Lisha Zhou; Chenyang Zhang; Qiang Xu; Yang Sun
Journal:  Signal Transduct Target Ther       Date:  2022-06-04

3.  Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells.

Authors:  Ganesh Babu Manoharan; Sunday Okutachi; Daniel Abankwa
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

4.  The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.

Authors:  Stephin J Vervoort; Sarah A Welsh; Jennifer R Devlin; Elisa Barbieri; Deborah A Knight; Sarah Offley; Stefan Bjelosevic; Matteo Costacurta; Izabela Todorovski; Conor J Kearney; Jarrod J Sandow; Zheng Fan; Benjamin Blyth; Victoria McLeod; Joseph H A Vissers; Karolina Pavic; Ben P Martin; Gareth Gregory; Elena Demosthenous; Magnus Zethoven; Isabella Y Kong; Edwin D Hawkins; Simon J Hogg; Madison J Kelly; Andrea Newbold; Kaylene J Simpson; Otto Kauko; Kieran F Harvey; Michael Ohlmeyer; Jukka Westermarck; Nathanael Gray; Alessandro Gardini; Ricky W Johnstone
Journal:  Cell       Date:  2021-05-17       Impact factor: 66.850

5.  Detection of genomic structure variants associated with wrinkled skin in Xiang pig by next generation sequencing.

Authors:  Liu Xiaoli; Hu Fengbin; Huang Shihui; Niu Xi; Li Sheng; Wang Zhou; Ran Xueqin; Wang Jiafu
Journal:  Aging (Albany NY)       Date:  2021-11-27       Impact factor: 5.682

6.  PP2A/B55α substrate recruitment as defined by the retinoblastoma-related protein p107.

Authors:  Holly Fowle; Ziran Zhao; Qifang Xu; Jason S Wasserman; Xinru Wang; Mary Adeyemi; Felicity Feiser; Alison N Kurimchak; Diba Atar; Brennan C McEwan; Arminja N Kettenbach; Rebecca Page; Wolfgang Peti; Roland L Dunbrack; Xavier Graña
Journal:  Elife       Date:  2021-10-18       Impact factor: 8.140

7.  Genetic Variant of PP2A Subunit Gene Confers an Increased Risk of Primary Liver Cancer in Chinese.

Authors:  Youxin Wang; Qiuyue Huang; Xinglei Huang; Huiliu Zhao; Bin Guan; Kechen Ban; Xuefeng Zhu; Zhixing Ma; Yanmei Tang; Zhaohui Su; Qingqing Nong
Journal:  Pharmgenomics Pers Med       Date:  2021-12-01

8.  eIF3a-PPP2R5A-mediated ATM/ATR dephosphorylation is essential for irinotecan-induced DNA damage response.

Authors:  Chao Mei; Ze-En Sun; Li-Ming Tan; Jian-Ping Gong; Xi Li; Zhao-Qian Liu
Journal:  Cell Prolif       Date:  2022-02-21       Impact factor: 8.755

Review 9.  PP2A and tumor radiotherapy.

Authors:  Xiao Lei; Na Ma; Lehui Du; Yanjie Liang; Pei Zhang; Yanan Han; Baolin Qu
Journal:  Hereditas       Date:  2020-08-26       Impact factor: 3.271

10.  PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers centrosome destabilization.

Authors:  Ziran Zhao; Alison Kurimchak; Anna S Nikonova; Felicity Feiser; Jason S Wasserman; Holly Fowle; Tinsa Varughese; Megan Connors; Katherine Johnson; Petr Makhov; Cecilia Lindskog; Vladimir M Kolenko; Erica A Golemis; James S Duncan; Xavier Graña
Journal:  Oncogenesis       Date:  2019-12-10       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.